Literature DB >> 12690505

Production and characterization of a monoclonal antibody for sweat-specific protein and its application for sweat identification.

Kazunori Sagawa1, Akihiko Kimura, Yoshifumi Saito, Hiroshi Inoue, Seiji Yasuda, Mizuho Nosaka, Tsutomu Tsuji.   

Abstract

Identification of body fluids is a common task in medico-legal practice, but specific markers for sweat have not been identified to date. To develop a method for identification of sweat, we identified a sweat-specific protein and produced monoclonal antibodies by immunizing mice with sweat proteins fractionated by anion-exchange chromatography. Among many sweat-reactive monoclonal antibodies obtained, one monoclonal antibody (G-81) was selected because of its unique specificity. G-81 reacted to sweat but not to other body fluids (e.g. serum, saliva, semen, milk, urine and tears) in ELISA. G-81 specifically stained the eccrine sweat gland and did not stain any other tissue including the apocrine sweat gland. In western blotting, G-81 reacted strongly to a 7 kDa band and faintly to 20, 27 and 33 kDa bands of sweat protein. The N-terminal amino acid sequence (18 amino acids) of G-81-reactive peptides was determined, and an identical sequence was found in an antibiotic peptide dermcidin (110 amino acids) reported recently, suggesting that G-81 recognized a fragment of dermcidin. The G-81-reactive peptide could be detected in 8,192-fold dilutions of sweat by ELISA and could be detected in 200-fold diluted sweat samples ( n=26) independent of the protein concentration. The G-81-reactive peptide was very stable and was able to detect sweat stains left for at least 11 weeks at room temperature without substantial loss of reactivity. These facts suggest that G-81 is a very useful tool for sweat identification in medico-legal practice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12690505     DOI: 10.1007/s00414-002-0341-8

Source DB:  PubMed          Journal:  Int J Legal Med        ISSN: 0937-9827            Impact factor:   2.686


  8 in total

1.  Development of a psilocin immunoassay for serum and blood samples.

Authors:  C Albers; H Köhler; M Lehr; B Brinkmann; J Beike
Journal:  Int J Legal Med       Date:  2004-08-03       Impact factor: 2.686

2.  Comparison of laser and mercury-arc lamp for the detection of body fluids on different substrates.

Authors:  S Seidl; R Hausmann; P Betz
Journal:  Int J Legal Med       Date:  2007-10-30       Impact factor: 2.686

3.  Quantitative proteomics of the human skin secretome reveal a reduction in immune defense mediators in ectodermal dysplasia patients.

Authors:  Marc Burian; Ana Velic; Katarina Matic; Stephanie Günther; Beatrice Kraft; Lena Gonser; Stephan Forchhammer; Yvonne Tiffert; Christian Naumer; Michael Krohn; Mark Berneburg; Amir S Yazdi; Boris Maček; Birgit Schittek
Journal:  J Invest Dermatol       Date:  2014-10-27       Impact factor: 8.551

4.  HPLC with laser-induced native fluorescence detection for morphine and morphine glucuronides from blood after immunoaffinity extraction.

Authors:  Y Hupka; J Beike; J Roegener; B Brinkmann; G Blaschke; H Köhler
Journal:  Int J Legal Med       Date:  2005-01-19       Impact factor: 2.686

5.  The applicability of ELISA detection of gastric mucosa-expressing proteins for the identification of vomit.

Authors:  Tomoko Akutsu; Hisako Saito; Hirotaro Iwase; Ken Watanabe; Ayari Takamura; Koichi Sakurada; Sachio Miyasaka
Journal:  Int J Legal Med       Date:  2016-06-27       Impact factor: 2.686

6.  Expression of dermcidin in human sinonasal secretions.

Authors:  Elizabeth E Cottrill; Bei Chen; Nithin D Adappa; James N Palmer; David W Kennedy; Robert J Lee; Noam A Cohen
Journal:  Int Forum Allergy Rhinol       Date:  2016-09-21       Impact factor: 3.858

7.  Highly abundant defense proteins in human sweat as revealed by targeted proteomics and label-free quantification mass spectrometry.

Authors:  É Csősz; G Emri; G Kalló; G Tsaprailis; J Tőzsér
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-08-25       Impact factor: 6.166

8.  Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.

Authors:  Jasna Bancovik; Dayson F Moreira; Daniel Carrasco; Jun Yao; Dale Porter; Ricardo Moura; Anamaria Camargo; Cibely C Fontes-Oliveira; Miguel G Malpartida; Silvia Carambula; Edouard Vannier; Bryan E Strauss; Alda Wakamatsu; Venancio Af Alves; Angela F Logullo; Fernando A Soares; Kornelia Polyak; José E Belizário
Journal:  BMC Cancer       Date:  2015-02-19       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.